Hydralyte

Q4 FY23 Quarterly Report and Appendix 4C: Net Cash Used in Operating Activities Down 56% YoY to Record Low

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte” or “the Company”) is pleased to provide the following update on its operational and financial performance for the three-month period ended 31 December 2023 (the “quarter”).

KEY HIGHLIGHTS

  • Net operating expenditure down 56% on PCP to US$1.14m (Q4 FY22: US$2.62m) and down 21% on prior quarter (Q3 FY23: US$1.46m) to lowest since listing in December 2021
  • Additional cost cutting initiatives continued post quarter end - includes payroll cuts annualised at over US$0.6m amongst others
  • Gross margin increased 12% on PCP (Q4 FY22: 48%) and 2% on last quarter (Q3 FY23: 58%) to 60%
  • YoY Gross Profit dollars up 4% to US$1.26m from US$1.21m in Q4 FY22
  • Q4 FY23 net sales of US$2.11m – a slight decrease on last quarter due to temporary out-of- stocks on effervescent tablets
  • Once-off out of stocks during the period led to estimated unfulfilled orders of ~US$0.6m, which had an estimated negative net sales impact of ~US$0.5m; out of stock actively rectified with multiple shipments received
  • Q4 FY23 sales also impacted by continued focus on high-margin revenue streams, sacrificing less profitable and lower margin revenue
  • FY23 total unaudited net sales of US$10m – a 9% increase on PCP (FY2022: US$9.09m)
  • Marketing costs as a percentage of net revenue reduced to 43% - down from 94% in Q4 FY22
  • Transition to new broker, LeBeau Excel, continues to expand addressable market in Canada and underpin 2-3% improvement in customer net margin
  • Ongoing work undertaken to launch high growth ready-to-drink (RTD) product range – manufacturing agreements and purchase orders pending
  • Continued execution of strategy to reduce expenditure and extend cash reserves through reduced marketing spend following significant investments in CY2022 to build and establish brand awareness in the North American market
Financial overview:

Revenue for the quarter was US$2.11m, which was a decrease on the PCP and previous quarter. The decline was due to multiple factors, which included temporary out of stocks and the prioritisation of improved profitability over revenue growth.

Temporary out of stocks during the period led to estimated unfulfilled orders of US$0.6m, which had a negative net sales impact of US$0.5m. The primary out of stocks were on multiple flavours of effervescent tablets and highlight the ongoing demand for HPC’s product suite.

The Company expects a swift recovery from the temporary issue and has received several shipments to improve the situation. Hydralyte expects to realise additional sales from these new shipments during the current quarter and will continue to work to capitalise on the strong demand for the Company’s products with North American retailers.

Sales through Amazon Canada increased 35% to CAD$0.5m, when compared to the PCP (Q4 FY2022 CAD$0.4m), while US Amazon sales were US$0.5, down slightly due to the Company’s ongoing shift towards improved profitability over revenue growth.

To drive more sustainable revenue growth, the Company is actively shifting product marketing investments towards higher conversion and higher margin products. This was highlighted by the decrease in marketing as a percentage of sales to 43% from PCP (Q4 FY2022 94%) and a 62% decrease in total marketing spend on the PCP (Q4 FY22: US$2.38m) to US$0.91m, in line with the Company’s cash preservation initiatives.


Click here for the full ASX Release

This article includes content from The Hydration Pharmaceuticals Company Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

HPC:AU
The Conversation (0)

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025.

Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 38,600 shares of Adicet's common stock with an exercise price of $0.76 per share, the closing price of Adicet's common stock as reported by Nasdaq on March 31, 2025. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the remaining three-fourths of the shares underlying each employee's option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the recipient's start date, in each case, subject to each such employee's continued employment with Adicet on such vesting dates.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
AbbVie to Host First-Quarter 2025 Earnings Conference Call

AbbVie to Host First-Quarter 2025 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025 before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that day.

About AbbVie

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.

Details of the event are as follows:
Panel: "CAR T Approaches in the Autoimmune Space"
Date: Monday, April 7, 2025
Time: 3:00 p.m. ET

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Issues Open Letter to Atea's Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers

Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

  • Four expert-led educational events with Allergan Medical Institute (AMI), Science of Aging TM and Allergan Aesthetics (AA) Global Medical Affairs
  • AMI symposia will focus on a new Allergan Aesthetics (AA) Signature Program and celebrate 10 years of MD Codes™, with live injection sessions and fireside chat with world-renowned plastic surgeon Dr. Maurício de Maio
  • Eleven E-Poster data presentations and Meet the Expert sessions with Global experts live from the Allergan Aesthetics booth

Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment outcomes with new AA Signature program at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Thursday, March 27Saturday, March 29, 2025 .

Activities will center around the new AA Signature program - an innovative approach to treatment planning harnessing the power of Allergan Aesthetics advanced portfolio to address different patient needs, including Lift, Definition and Skin Quality , and a celebration of 10 years of MD Codes™, which has revolutionized aesthetic medicine with innovative methodology to guide injectors' technique and elevate patient outcomes.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Bcal Diagnostics Limited

BCAL Diagnostics Launches BREASTEST plus - Generating First Revenues

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”), an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics, is pleased to announce the commercial launch of BREASTEST plus. This first-in-class blood test is available from Thursday, 27 March 2025 and will be used alongside standard-of-care imaging in breast cancer screening and diagnostics. The Company is pleased that this launch has been achieved within the previously announced target timeframe of having the test commercially available in Australia by the end of 1Q CY2025.

Keep reading...Show less

Latest Press Releases

Related News

×